clinical trial · NCT06561360
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Hairy Cell LeukemiaVemurafenibObinutuzumabCladribineRituximab
brief summary
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective at eliminating cancer cells.
started
Sep 9, 2024
primary completion
Sep 9, 2027
completion
Sep 9, 2027
last updated
Apr 15, 2026
official title
A Randomized, Multi-Center, Phase II Study of Vemurafenib Plus Obinutuzumab vs. Cladribine Plus Rituximab in Patients With Previously Untreated Hairy Cell Leukemia (HCL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol